Is normal esophageal acid exposure on pH monitoring in Barrett's patients maintained on repeated testing?

Banerjee, Promila; Ahmad, Fawzia; Tutuian, Radu; Gideon, R. Matthew; Castell, Donald O.; Katz, Philip O.

doi:10.1016/s0016-5085(03)82727-0

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, recent studies have shown that oesophageal acid exposure can be normalized in only 80–85% of patients with Barrett's oesophagus treated with twice‐daily PPIs (Figure 7). 22, 23 In this setting, and in patients with other forms of refractory GERD, overnight breakthrough of gastric acid is clearly of clinical importance.…”

Section: Unmet Needs In Gerdmentioning

confidence: 99%

Review article: acid‐related disease – what are the unmet clinical needs?

Katz

Scheiman

Barkun

2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYProton pump inhibitors have dramatically improved the management options available for patients with acid-related disorders.In patients with gastro-oesophageal reflux disease, currently available proton pump inhibitors provide an excellent outcome for the majority; however, they do not provide optimal pH control in many. Proton pump inhibitors co-therapy reduces, but does not eliminate, the risk of gastrointestinal ulcers and complications in patients taking non-steroidal anti-inflammatory drugs, while in patients with upper gastrointestinal bleeding, it may be difficult to reach and maintain the current therapeutic target of intragastric pH of 6-7.This article reviews the effectiveness of current antisecretory therapy in these three acid-related diseases and areas of unmet clinical need. The potential role of a proton pump inhibitor with an extended duration of action and enhanced acid control from a single daily dose, particularly improved control at night, is discussed. Finally, therapy that could be administered without regard to time of day and/or food intake would offer dosing flexibility and thus have a positive effect on patients' compliance.

show abstract

Section: Unmet Needs In Gerdmentioning

confidence: 99%

Review article: acid‐related disease – what are the unmet clinical needs?

Katz

Scheiman

Barkun

2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“… Normalization of oesophageal acid control in 78 patients with Barrett's oesophagus. PPI, proton‐pump inhibitor; >PPI, higher dose PPI; H 2 RA, histamine‐2 receptor antagonist; Cis, cisapride (adapted from Banerjee et al 9 …”

Section: Nocturnal Acid and Barrett's Oesophagusmentioning

confidence: 99%

“…Normalization of night‐time acid exposure in patients with Barrett's oesophagus remains challenging. A comparison of various PPI regimens in patients with Barrett's oesophagus found that once daily PPI therapy only normalized oesophageal acid exposure about 30% of the time (Figure 1), 9 and even higher doses of an H 2 RA at bedtime do not normalize all patients. Two prospective studies have reinforced that twice daily dosing with PPIs (rabeprazole 20 mg or esomeprazole 40 mg) will normalize oesophageal acid exposure in about 71–77% of patients 10, 11 .…”

Section: Nocturnal Acid and Barrett's Oesophagusmentioning

confidence: 99%

Review article: putting immediate‐release proton‐pump inhibitors into clinical practice – improving nocturnal acid control and avoiding the possible complications of excessive acid exposure

Katz

2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Nocturnal gastro‐oesphageal reflux is an under‐appreciated clinical challenge. This condition may cause symptoms such as nocturnal heartburn, or it may be asymptomatic. In addition, patients may experience sleep disturbances that can potentially lead to complications such as erosive oesophagitis and Barrett's oesophagus, and may be a risk factor for development of oesophageal adenocarcinoma. Delayed‐release proton‐pump inhibitors (PPIs) have traditionally been effective in treating both daytime and night‐time reflux symptoms, but are limited in control of nocturnal acidity by their pharmacodynamic characteristics. This narrative review addresses the prevalence, impact and pharmacologic approaches used to control nocturnal acidity. Methods to optimize nocturnal acid control include careful attention to dosing schedule, using higher doses of PPIs, adding an histamine H2‐receptor antagonist at bedtime to once or twice daily delayed‐release PPI, or using immediate‐relase omeprazole (Zegerid powder for oral suspension; Santarus, Inc., San Diego, CA, USA). This new formulation appears to provide sustained control of intragastric pH at steady state, and when dosed at bedtime, and may be effective in improving control of nocturnal pH and treating night‐time GERD.

show abstract

Is normal esophageal acid exposure on pH monitoring in Barrett's patients maintained on repeated testing?

Cited by 2 publications

References 0 publications

Review article: acid‐related disease – what are the unmet clinical needs?

Review article: acid‐related disease – what are the unmet clinical needs?

Review article: putting immediate‐release proton‐pump inhibitors into clinical practice – improving nocturnal acid control and avoiding the possible complications of excessive acid exposure

Contact Info

Product

Resources

About